Response to: ‘Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors’ by Meyer et al

Published on Jan 21, 2020in Annals of the Rheumatic Diseases14.299
· DOI :10.1136/annrheumdis-2019-216598
Michelle Rosenzwajg29
Estimated H-index: 29
Roberta Lorenzon3
Estimated H-index: 3
David Klatzmann63
Estimated H-index: 63
Commenting on Meyer et al 1 our recent publication2 ‘Immunological and clinical effects of low-dose interleukin-2 (IL-2) across 11 autoimmune diseases in a single, open clinical trial’, Dr Meyer and colleagues point to the issue of concomitant background therapies that could affect the effects of low-dose IL-2. They reported a significant increase of Treg cell frequencies in peripheral blood of patients with rheumatoid arthritis treated with methotrexate, adalimumab, etanercept, golimumab and tocilizumab, which they discuss could affect the increase expected after an IL-2 treatment. Only four rheumatoid arthritis patients were included in our study, all being treated with low-dose corticosteroids and/or low doses of immunosuppressants. Their baseline Treg evaluation was similar to that of patients with other diseases treated with …
  • References (4)
  • Citations (0)
📖 Papers frequently viewed together
3 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Anja Meyer (University of Cologne)
#2Paula S. Wittekind (University of Cologne)
Last. David M. Kofler (University of Cologne)H-Index: 14
view all 7 authors...
Regulatory T (Treg) cells play an important role in controlling immune responses. Their frequency is decreased in many autoimmune diseases, including rheumatoid arthritis (RA). We read with great interest the article by Rosenzwajg et al which presents the results of a clinical trial with low-dose interleukin-2 (ld-IL-2).1 The authors report that Treg cell frequencies were significantly increased following ld-IL-2 administration in 46 patients with autoimmune diseases. Among them, four patients h...
1 CitationsSource
Objective Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential. Aim We aimed to assess this potential and select diseases for further clinical development by cross-investigating the effects of ld-IL2 in a single clinical trial treating patients with 1 of 11 autoimmune diseases. Methods We perfo...
22 CitationsSource
The dominant role of interleukin-2 (IL-2) is in the maintenance of regulatory T cells rather than of effector T cells. This has led to clinical interest in the use of low-dose IL-2 to control autoimmune and inflammatory disorders, with promising initial results.
215 CitationsSource
#1Michelle Rosenzwajg (French Institute of Health and Medical Research)H-Index: 29
#2Guillaume Churlaud (French Institute of Health and Medical Research)H-Index: 8
Last. David Klatzmann (French Institute of Health and Medical Research)H-Index: 63
view all 16 authors...
Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector T cells (Teffs) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression has long been the only therapeutic option, activating/expanding Tregs may achieve the same objective without the toxicity of immunosuppression. We showed that low-dose interleukin-2 (ld-IL-2) safely expands/activates Tregs in patients with AID, such HCV-induced vasculitis and Type 1 Diabetes (T1D). Here we analyzed the...
92 CitationsSource
Cited By0